logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Urban construction development: Received Huawei Capital's second dividend of 23.625 million yuan for the year 2024.

date
29/09/2025
Urban Construction Development Announcement: The company holds 280 million shares of Huaneng Capital Services Co., Ltd., accounting for 2.86% of its total share capital. Recently, the company received a second dividend payment of 23.625 million yuan for the year 2024 from Huaneng Capital, which will be included in the company's investment income for the year 2025.
Latest
1 m ago
British Chancellor of the Exchequer Rishi Sunak: The government will push forward with plans for the Northern Railways.
2 m ago
Spot gold continued to rise to a new high of $3820 per ounce, with an intraday increase of over $60. US gold stocks collectively rose in pre-market trading, with Kirkland Lake Gold up over 3%, and Kinross Gold, Newmont Mining, and Agnico Eagle Mines up over 2%.
3 m ago
Wens Foodstuffs: The company suffered certain losses in assets in parts of Guangdong region due to the impact of Typhoon Hujia.
3 m ago
Lion Rock Holdings (02562.HK) appoints Wu Dongcheng as the company secretary and legal process agent.
3 m ago
Kangchen Pharmaceutical: KC1036 combined with PD-1 antibodies and platinum-containing chemotherapy for first-line treatment of advanced recurrent or metastatic esophageal squamous cell carcinoma obtained a clinical trial notification.
See all latestmore
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.